Canada markets open in 1 hour 47 minutes

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8000-0.2700 (-8.79%)
At close: 04:00PM EDT
2.9000 +0.10 (+3.57%)
Pre-Market: 07:20AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

    Topline data anticipated in late September 2024WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability o

  • GlobeNewswire

    Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates. “The second quarter of 2024 was marked with significant progress with our lead asset, istaroxime in development for the treatment of cardiogenic shock

  • GlobeNewswire

    Windtree Announces New Additions and Changes to Its Board of Directors

    WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of directors, effective August 13, 2024, which include the appointment of Saundra Pelletier and Jed Latkin as two new independent directors with significant public company director and executive leadership. Join